Prodrugs of dynemicin analogs were synthesized, and their activation by aldolase antibody (Ab) 38C2 was evaluated by DNAcleaving activity, as well as tumor cell growth inhibition. Further, we provide evidence that the activated enediynes underwent covalent crosscoupling with the aldolase Ab, which appears to be a limiting factor of their tumor cell growth-inhibiting activity and should be of general interest in the field of enediyne chemotherapy. These findings might open new avenues for defined conjugations of small molecule drugs to mAbs in general and aldolase Abs in particular.T he specific elimination of cancer cells with potent chemotherapeutic agents is limited by their inability to selectively target cancerous cells. To overcome the nonselectivity of the chemotherapy, new approaches, including Ab-directed enzyme prodrug therapy, have been developed. (1-3) In the Ab-directed enzyme prodrug therapy approach, an enzyme is directed to the tumor cells by using a targeting Ab, which selectively recognizes a cancer-associated cell-surface antigen. After the enzyme-Ab conjugate has localized at the tumor site and cleared from the periphery, a prodrug of a potent chemotherapeutic agent is administered. The prodrug is then activated by the enzyme-Ab conjugate selectively at the tumor site, thereby reducing the toxicity to normal tissue. Based on well documented achievements in Ab-mediated cancer therapy, the targeting Ab component for this strategy is often readily available. The requirements for the enzyme component and complementary prodrug, however, have remained elusive.With the discovery of catalytic Abs, (4, 5) several research groups suggested that mAbs could be used to replace the enzyme component of the Ab-directed enzyme prodrug therapy approach. (6-8) Using an mAb as the catalyst could (i) access reactions that are not catalyzed by endogenous enzymes, and (ii) reduce the immunogenicity of the catalyst through Ab humanization. (9) Thus, recent studies (10) using catalytic aldolase mAb, 38C2, to activate prodrugs of several anticancer drugs, including doxorubicin, etoposide, and camptothecin, have opened another front in the Ab-directed enzyme prodrug therapy approach. (11, 12) These prodrugs contained a linker, which involved an aldol and an oxa-Michael motif in a sequence. Both the aldol and the oxa-Michael motifs were stable in the absence of the catalyst 38C2, but they readily underwent retro-aldol and -elimination reactions in the presence of a catalytic amount of mAb 38C2 releasing the active drugs. This chemistry by using catalyst 38C2 is further desirable for the activation of a prodrug because there are no native enzymes in vivo that catalyze this reaction, thus background activation is diminished. Hence, we are developing prodrugs of additional anticancer compounds, including enediynes, which are extremely toxic. (13,14) In this article, we describe the synthesis of the prodrugs of the simplified analogs (2) of a highly toxic enediyne, dynemicin A (1; Fig. 1), and the in vitro evaluation of the...